Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
SSE:603707.SS
11.31 (CNY) • At close June 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | ||||||||||||
| Net Income
| 826.099 | -189.447 | 1,086.519 | 1,063.916 | 796.655 | 606.242 | 424.549 | 314.222 | 257.24 | 87.553 | 50.46 | 70.314 |
| Depreciation & Amortization
| 174.854 | 154.06 | 139.532 | 93.222 | 84.549 | 44.989 | 39.868 | 40.934 | 37.175 | 17.522 | 13.521 | 8.893 |
| Deferred Income Tax
| 0 | 0 | -28.37 | -11.471 | -8.375 | -8.659 | -0.133 | -0.112 | 0.034 | -0.687 | 0 | 0 |
| Stock Based Compensation
| 0 | 42.851 | 28.364 | 8.979 | 8.386 | 1.373 | 1.349 | 0 | 0 | 0 | 0 | 0 |
| Change In Working Capital
| 399.765 | 355.393 | -506.386 | -556.905 | -1,565.588 | -1,502.541 | -400.517 | -577.236 | -458.101 | 55.796 | 127.677 | 116.539 |
| Accounts Receivables
| -13.188 | 163.365 | -1,456.21 | -148.203 | -345.267 | -202.112 | -48.299 | -188.668 | -98.278 | 48.925 | -30.316 | 0 |
| Inventory
| 598.72 | 213.283 | -731.569 | -444.053 | -1,223.18 | -1,230.125 | -655.306 | -618.77 | -379.847 | 44.618 | 114.097 | 20.92 |
| Accounts Payables
| 0 | 0 | 1,709.763 | 46.823 | 11.233 | -61.645 | 303.221 | 230.312 | 19.991 | -37.061 | 0 | 0 |
| Other Working Capital
| -185.767 | -21.255 | -28.37 | -11.471 | -8.375 | -8.659 | 254.789 | 41.533 | -78.254 | 11.178 | 13.58 | 95.618 |
| Other Non Cash Items
| 100.511 | 1,256.311 | -122.773 | 85.892 | 118.524 | 17.215 | -1.532 | -12.507 | -123.1 | -23.591 | -12.917 | -1.832 |
| Operating Cash Flow
| 1,501.228 | 1,619.168 | 595.446 | 683.632 | -565.848 | -841.381 | 62.368 | -234.586 | -286.787 | 137.281 | 178.741 | 193.913 |
| Investing Activities: | ||||||||||||
| Investments In Property Plant And Equipment
| -506.82 | -419.068 | -470.078 | -440.758 | -294.363 | -115.406 | -82.761 | -81.137 | -72.508 | -24.87 | -29.397 | -61.957 |
| Acquisitions Net
| 0 | 0 | 0.112 | -13.87 | 0.117 | -25.577 | 82.819 | 0.012 | 0.161 | 0.216 | 8.665 | 0 |
| Purchases Of Investments
| -3,618.408 | -2,331.36 | -2,000.12 | -3,149.263 | -2,590.519 | -1,745.663 | -2,661.582 | -2,117.5 | -1,082.9 | -2,007.8 | -1,655.402 | -925 |
| Sales Maturities Of Investments
| 3,214.494 | 1,573.893 | 2,069.591 | 3,773.495 | 1,710.944 | 1,732.715 | 2,948.537 | 1,603.294 | 1,278.612 | 2,085.742 | 1,446.938 | 937.91 |
| Other Investing Activites
| 0.002 | 0.153 | 0 | 0.54 | 1.032 | 0.313 | -82.761 | 2.4 | 16.173 | -0.046 | 8.839 | 4.6 |
| Investing Cash Flow
| -910.732 | -1,176.382 | -400.496 | 170.143 | -1,172.79 | -153.618 | 204.251 | -592.93 | 139.538 | 53.242 | -220.357 | -44.447 |
| Financing Activities: | ||||||||||||
| Debt Repayment
| -502.888 | 308.371 | -80.552 | -559.863 | 761.727 | 1,048.42 | -2.93 | 0 | 18.909 | -291.745 | 305.696 | -84.152 |
| Common Stock Issued
| 0 | 0 | 1.13 | 0.874 | 1.039 | 2.388 | 0 | -34.09 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased
| 0 | -5.722 | -1.13 | -0.874 | -1.039 | -2.388 | -0.067 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid
| -213.195 | -248.469 | -186.586 | -140.406 | -215.574 | -82.901 | -73.101 | -3.003 | -37.949 | -31.491 | -40.234 | -48.655 |
| Other Financing Activities
| -15.197 | -2.98 | -42.545 | -159.902 | 1,472.782 | 3.604 | 20.278 | 660.747 | 0 | 314.662 | -289.662 | 0 |
| Financing Cash Flow
| -731.28 | 51.2 | -310.812 | -912.39 | 1,973.302 | 951.381 | -55.82 | 623.654 | -19.04 | -8.574 | -24.2 | -132.807 |
| Other Information: | ||||||||||||
| Effect Of Forex Changes On Cash
| -16.705 | 83.184 | -16.111 | 20.046 | -9.885 | 4.409 | 6.896 | 8.121 | 1.175 | 4.17 | 0.176 | -4.012 |
| Net Change In Cash
| -157.488 | 591.51 | -131.973 | -38.57 | 224.78 | -39.209 | 217.695 | -195.742 | -165.115 | 186.12 | -65.64 | 12.648 |
| Cash At End Of Period
| 736.697 | 894.185 | 302.675 | 434.648 | 473.218 | 248.438 | 287.647 | 69.951 | 265.693 | 430.807 | 244.688 | 310.328 |